PLA2R1 Overexpression Causes Podocyte Injury by Inhibiting the Cell Cycle: A Clinical Cross-Sectional Investigation and Cellular Study
Wei Liang,1,2 Hua Zhang,2 Yi Wu,3 Zhiwei Lai,2 Weiqiang Zhang,3 Yuhao Cao,4 Lishan Tan,2 Zibo Xiong,2 Guang Yang,2 Zuying Xiong1,2 1Department of Nephrology, School of Clinical Medicine, Peking University Shenzhen Hospital, Anhui Medical University, Shenzhen, Guangdong, 518036, People’s Republic of...
Saved in:
| Main Authors: | Liang W, Zhang H, Wu Y, Lai Z, Zhang W, Cao Y, Tan L, Xiong Z, Yang G |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-06-01
|
| Series: | International Journal of Nephrology and Renovascular Disease |
| Subjects: | |
| Online Access: | https://www.dovepress.com/pla2r1-overexpression-causes-podocyte-injury-by-inhibiting-the-cell-cy-peer-reviewed-fulltext-article-IJNRD |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of Time-To-Treatment on Outcomes in Autoimmune Membranous Nephropathy
by: Patrick Hamilton, et al.
Published: (2025-06-01) -
How to Choose Treatment Regimens for Idiopathic Membranous Nephropathy Patients with PLA2R-Negative: A Single-Center Retrospective Cohort Study
by: Zhou Z, et al.
Published: (2025-05-01) -
Obinutuzumab for treatment of membranous nephropathy in patients positive and negative for the phospholipase A2 receptor antibody: case reports
by: Jinmeng Wang, et al.
Published: (2025-04-01) -
Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial
by: Li XQ, et al.
Published: (2025-07-01) -
Sulforaphane alleviates membranous nephropathy by inhibiting oxidative stress-associated podocyte pyroptosis
by: Daoyuan Lv, et al.
Published: (2025-02-01)